Automate Your Wheel Strategy on BIIB
With Tiblio's Option Bot, you can configure your own wheel strategy including BIIB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BIIB
- Rev/Share 68.1173
- Book/Share 124.1985
- PB 1.4232
- Debt/Equity 0.3619
- CurrentRatio 2.7163
- ROIC 0.0796
- MktCap 25931093599.0
- FreeCF/Share 15.5348
- PFCF 11.3863
- PE 16.1101
- Debt/Assets 0.2256
- DivYield 0
- ROE 0.0925
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | BIIB | UBS | -- | Neutral | -- | $185 | Jan. 7, 2026 |
| Downgrade | BIIB | HSBC Securities | Hold | Reduce | -- | $143 | Dec. 10, 2025 |
| Upgrade | BIIB | Stifel | Hold | Buy | -- | $202 | Nov. 6, 2025 |
| Initiation | BIIB | Jefferies | -- | Buy | -- | $190 | Sept. 25, 2025 |
| Resumed | BIIB | Truist | -- | Hold | -- | $142 | July 21, 2025 |
| Downgrade | BIIB | HSBC Securities | Buy | Hold | -- | $118 | April 28, 2025 |
| Downgrade | BIIB | Argus | Buy | Hold | -- | -- | April 4, 2025 |
| Initiation | BIIB | Bernstein | -- | Market Perform | -- | $160 | Feb. 11, 2025 |
| Downgrade | BIIB | Piper Sandler | Overweight | Neutral | $315 | $138 | Jan. 2, 2025 |
| Downgrade | BIIB | BMO Capital Markets | Outperform | Market Perform | $230 | $164 | Dec. 20, 2024 |
News
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.
Read More
The Nasdaq is Cratering But REGN, BIIB and CSGP Are Up Big Today
Published: March 10, 2025 by: 24/7 Wall Street
Sentiment: Negative
If you're one of the over 4 Million Americans set to retire this year, you may want to pay attention.
Read More
Biogen Stock Is Mutating Into a Value Play
Published: February 20, 2025 by: MarketBeat
Sentiment: Neutral
Biogen Inc. NASDAQ: BIIB has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology company is trading at historically low valuations at a 12.41 price-earnings (P/E) ratio, which is less than half of the industry average P/E of 29.52.
Read More
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Published: February 18, 2025 by: Market Watch
Sentiment: Positive
Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.
Read More
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen's rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront, shared development costs and is eligible to receive up to $385M in milestones as well as royalties CAMBRIDGE, Mass. and BEDFORD, Mass.
Read More
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
Published: February 13, 2025 by: Benzinga
Sentiment: Positive
On Wednesday, Biogen Inc BIIB reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35.
Read More
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.
Read More
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (NASDAQ:BIIB ) Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Tim Power - Head of IR Chris Viehbacher - President and CEO Priya Singhal - Head of Development Mike McDonnell - CFO Conference Call Participants Salveen Richter - Goldman Sachs Michael Yee - Jefferies Tim Anderson - Bank of America Brian Abrahams - RBC Capital Markets Marc Goodman - Leerink Paul Matteis - Stifel Umer Raffat - Evercore ISI Chris Schott - JPMorgan Evan Seigerman - BMO Capital Markets Phil Nadeau - TD Cowen Operator Good morning. My name is Jennifer and I …
Read More
Biogen's stock hit by soft guidance and a decline in sales of MS drugs
Published: February 12, 2025 by: Market Watch
Sentiment: Negative
Sales of an Alzheimer's disease treatment were better than expected, but that and a quarterly beat wasn't enough to offset below-consensus EPS outlook.
Read More
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Published: February 12, 2025 by: CNBC
Sentiment: Neutral
Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth. The biotech company issued a full-year 2025 adjusted earnings outlook of $15.25 to $16.25 per share, which fell short of the $16.34 per share that Wall Street was expecting.
Read More
Drugmaker Biogen forecasts 2025 profit below expectations
Published: February 12, 2025 by: Reuters
Sentiment: Negative
Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis.
Read More
Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Published: February 12, 2025 by: Benzinga
Sentiment: Neutral
Biogen Inc. BIIB will release its fourth-quarter financial results, before the opening bell, on Wednesday, Feb. 12, 2025.
Read More
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Read More
About Biogen Inc. (BIIB)
- IPO Date 1991-09-17
- Website https://www.biogen.com
- Industry Drug Manufacturers - General
- CEO Christopher A. Viehbacher
- Employees 7605